STRO-006 / Sutro Biopharma - LARVOL DELTA

A highly selective integrin β6 (ITGB6) ADC, STRO-006 is expected to enter clinical development in 2026 for the treatment of multiple solid tumors (GlobeNewswire)

New trial • Solid Tumor

Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire) - "Corporate and Program Updates:...STRO-006: Sutro’s differentiated integrin beta-6 (ITGB6) ADC is expected to enter clinical development in 2026, aimed at multiple solid tumors....21st Annual PEGS Boston: The Essential Proteins Engineering & Cell Therapy Summit: In May, Sutro will present promising preclinical data with STRO-006, highlighting its superior anti-tumor activity compared to first generation ITGB6 ADCs at clinically relevant dose levels, as well as its favorable PK and tolerability profile."

New trial • Preclinical • Solid Tumor

Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline (GlobeNewswire) - "STRO-006: Sutro’s differentiated integrin beta-6 ADC is expected to enter clinical development in 2026 aimed at multiple solid tumors."

IND • Solid Tumor